Why Market Timing Fails Even With Future Knowledge

The Market Timing Challenge

Picture this: wouldn’t it be incredible to possess foresight into upcoming events before they unfold? Envision the vast fortunes you could amass in the stock market with such an advantage. It sounds like the ultimate fantasy for any investor, doesn’t it?

However, what if I revealed that this supposed edge isn’t the goldmine you might imagine? What if having complete knowledge of future developments still leaves you at a disadvantage in terms of profitability?

This concept may seem counterintuitive, but I can demonstrate its validity through an engaging interactive exercise designed to highlight the pitfalls of market timing.

Playing the Market Timing Game

Let’s set the scene: it’s February 28, 2020. The COVID-19 outbreak is rapidly escalating across the globe, and the S&P 500 has already plummeted by approximately 12%. Amid the swirling uncertainty and fear, you choose to exit your positions in the stock market to safeguard your capital.

Suddenly, a mystical genie appears and offers you an extraordinary deal. This genie promises to reveal the genuine headlines that will dominate the news throughout the entire duration of the COVID-19 crisis. You’ll gain insights into vaccine discoveries and their timelines, approximate death tolls, and the eventual resolution of the pandemic.

There’s a crucial condition, though: upon receiving this prophetic information, you must immediately commit to a specific date for reinvesting in U.S. equities. No hesitation or observation of subsequent price movements allowed—you base your decision purely on the provided future headlines. Would you take the genie’s offer?

For the sake of this thought experiment, assume you agree. True to its word, the genie presents you with a curated list of real headlines drawn from official sources like the CDC’s timeline. These are:

• March 11, 2020: With over 118,000 cases reported across 114 countries and 4,291 fatalities, the World Health Organization officially labels COVID-19 a pandemic. The NBA suspends its season indefinitely. In the ensuing days, the Trump administration declares a national emergency, prompting widespread state-level lockdowns to curb the virus’s spread.
• March 17, 2020: Moderna Therapeutics initiates the inaugural human trials for a COVID-19 vaccine at a Seattle-based research center in Washington state.
• April 10, 2020: In less than four months, the U.S. records over 18,600 confirmed deaths and more than 500,000 cases, eclipsing Italy and Spain to become the world’s leading hotspot for the virus.
• May 28, 2020: The U.S. COVID-19 death toll exceeds 100,000 confirmed fatalities.
• September 28, 2020: Global COVID-19 deaths surpass 1 million, including 200,000 in the U.S. alone.
• November 16, 2020: Moderna’s vaccine demonstrates 95.4% efficacy in clinical trials. Just two days later, Pfizer-BioNTech reports 95% effectiveness from their large-scale 44,000-participant study.
• December 14, 2020: U.S. deaths from COVID-19 top 300,000. Nurse Sandra Lindsay in New York receives the first vaccine dose administered outside of trials.
• January 16, 2021: Over 23 million vaccine doses have been delivered across the United States, while worldwide cases exceed 100 million.
• February 21, 2021: The U.S. death toll from COVID-19 passes the grim milestone of 500,000.
• March 13, 2021: More than 100 million vaccine doses administered in the U.S.
• April 21, 2021: U.S. vaccine administrations surpass 200 million doses.
• March 3, 2022: The U.S. donates over 480 million vaccine doses to 110 nations worldwide.
• June 1, 2022: Cumulative U.S. figures stand at 84,145,569 infections and 1,003,571 deaths from COVID-19.
• May 5, 2023: The WHO revokes COVID-19’s status as a public health emergency of international concern.

Reviewing these headlines, you feel a mix of relief at the swift vaccine development and mass rollout, tempered by horror at the staggering loss of over 1 million lives in the U.S. Despite the emotional weight, the genie’s terms bind you to select a reinvestment date immediately, relying solely on this information and disregarding actual market performance. Which date from this sequence would you choose? Think carefully and respond candidly.

Personally, I would have selected November 15, 2020—the day immediately preceding the announcement of Moderna’s 95% vaccine efficacy. This marks the inaugural ray of unequivocally positive news amid the bleak updates. But was this the optimal decision?

Unfortunately, no. By delaying until then, I would have forfeited a substantial 23% appreciation in the S&P 500 from February 28, 2020, onward. For context, market enthusiasts recall that the S&P 500 reached its nadir on March 23, 2020. Thus, the superior choice from the provided headlines was March 17, 2020.

Reinvesting on March 17, 2020, would have delivered a robust 43% return by November 15, 2020:

What circumstances surrounded March 17, 2020? This was precisely when Moderna launched its initial human vaccine trials. At that juncture, no one could guarantee success—not Moderna, not experts. The U.S. death count represented under 2% of the final tally. Remarkably, this moment of tentative beginnings proved to be the prime entry point for investment.

Why Foreknowledge Doesn’t Guarantee Success

Does this illustrate the profound challenges inherent in market timing? Even when furnished with definitive future outcomes via these headlines, most individuals would still misjudge the optimal moment. Few fields exhibit this paradox, yet investing exemplifies it vividly. It echoes the infamous instance when Jane Street Capital gained early knowledge of Donald Trump’s 2016 election victory ahead of major networks and yet incurred a $300 million loss on their positions.

Throughout my career, I’ve meticulously constructed technical cases against market timing strategies, drawing on extensive data analyses in various publications. These efforts underscore how such approaches consistently underperform straightforward monthly purchasing—often termed dollar-cost averaging or a philosophy of relentless accumulation.

Yet, this analysis shifts to a more philosophical and logical critique. It bypasses empirical comparisons altogether, allowing intuitive recognition of why market timing constitutes an unwinnable endeavor.

Fundamentally, the stock market operates as a sophisticated mechanism for discounting information, incorporating not only raw data but also collective anticipations of that data into prices with remarkable swiftness. As investment luminary Barton Biggs articulated in his seminal work Wealth, War, & Wisdom:

> Markets function so efficiently because the totality of all relevant information including subjective preferences are aggregated through the price mechanism into a single market valuation which, while perhaps not perfect, is better than any number concocted by a human entity or even a computer.

Consequently, a solitary future headline provides scant predictive power over market trajectories. A headline captures merely the primary impact—the raw event itself. It overlooks investor interpretations, subsequent reactions to those interpretations, and cascading chain reactions. These second- and higher-order dynamics elude deduction from isolated facts.

Put simply, possessing future knowledge does not equip you to forecast collective market reactions to it.

This inherent unpredictability ensures no one can reliably time the market consistently. The requisite omniscience encompasses unknowable elements by nature. The market embodies a chaotic system, where minor variations in starting conditions can yield wildly divergent responses to new information—a phenomenon akin to the butterfly effect. Hence, perfect foresight notwithstanding, market timing remains elusive.

In practice, of course, future headlines remain firmly in the realm of fiction—no genie awaits to enlighten us.

I fully appreciate the seductive pull of market timing temptations. I’ve even yielded to them occasionally in recent years, adjusting portfolios based on bearish convictions. Yet, those instincts proved erroneous as markets surged regardless.

Even with concerns over inflated AI sector valuations—concerns echoed by valuation experts—it becomes evident that outpacing the market’s collective intelligence lies beyond individual grasp. Therefore, the prudent path forward is steady, unwavering accumulation over time.